Cipla, Eli Lilly Join Forces to Launch Tirzepatide in India as Yurpeak
Cipla and Eli Lilly India have announced an agreement to distribute a type 2 diabetes drug, tirzepatide, under the new brand name Yurpeak in India. This move aims to expand drug availability beyond cities, addressing the growing health concerns of diabetes and obesity in the country.
- Country:
- India
In a strategic alliance, Cipla and Eli Lilly and Company (India) unveiled plans to distribute and promote the type 2 diabetes drug tirzepatide in India, under the fresh brand name, Yurpeak.
This collaboration aims to enhance the accessibility of tirzepatide across India, particularly in areas beyond major cities, leveraging Cipla's expansive distribution network.
As India grapples with rising rates of type 2 diabetes and obesity, this partnership marks a significant step in providing wider access to innovative health solutions.
Advertisement
ALSO READ
-
Eli Lilly's Breakthrough Weight-Loss Drug Slated for Expedited FDA Review
-
UPDATE 5-Eli Lilly raises forecasts on surging international demand for weight-loss drugs
-
UPDATE 4-Eli Lilly raises forecasts on surging international demand for weight-loss drugs
-
Cipla Q2 profit up 3.7 pc at Rs 1,353 cr; Umang Vohra will not seek reappointment as MD, Global CEO
-
Cipla Q2 net up 3.7 pc at Rs 1,353.37 cr
Google News